Global Drugs For Benign Prostatic hypertrophy Market Report 2024

Drugs For Benign Prostatic hypertrophy Global Market Report 2023 – By Type (Alpha Blocker, 5alpha Reductase Inhibitor, Phosphodiesterase5 Inhibitor, Other Types), By End User (Hospital Pharmacies, Retail Pharmacies, Other EndUsers), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2023-2032

Starting Price : $5000.00 | Pages : 175 | Published : January 2023 | Delivery Time: 2-3 business days | Format : pdf

Need assistance or more information before the purchase?

Enquire Before Buying
Drugs For Benign Prostatic hypertrophy Market

Proud Members Of

checkslacipN checkaoirsN checkscipN

The drug benign prostatic hypertrophy refers to benign prostatic hypertrophy drugs that are used to treat enlarged prostate glands by relaxing bladder neck muscles and muscle fibres in the prostate, making urination easier. Benign Prostatic Hypertrophy is commonly seen in men older than 50.

The main types of drugs for benign prostatic hypertrophy are alpha-blockers, 5-alpha reductase inhibitors, phosphodiesterase-5 inhibitors, and others. Alpha-blockers, commonly known as "blockers" or "adrenoreceptor antagonists," are a type of pharmaceutical drug that works by blocking adrenergic receptors. The different sectors include hospital pharmacies, retail pharmacies, and others and are distributed through various channels, such as hospital pharmacies, retail pharmacies, and online pharmacies.

The global drugs for benign prostatic hypertrophy market is segmented -

1) By Type: Alpha Blocker, 5-alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, Other Types

2) By End User: Hospital Pharmacies, Retail Pharmacies, Other End-Users

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

The global drugs for benign prostatic hypertrophy market size will grow from $6.45 billion in 2022 to $6.86 billion in 2023 at a compound annual growth rate (CAGR) of 6.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global drugs for benign prostatic hypertrophy is expected to grow to $8.18 billion in 2027 at a CAGR of 4.5%.

The rising male geriatric population globally is driving the growth of drugs for benign prostatic hypertrophy market for Benign Prostatic Hypertrophy drugs as the condition is commonly seen in men aged over 50 years. According to the United Nations' 2019 World Population Ageing Report, the number of people aged 65 years or above was 703 million in 2019 and is expected to double to around 1.5 billion by 2050. According to the National Institute of Health (NIH), Benign Prostatic Hyperplasia affects around 50% of men aged between 51 and 60 years and up to 90% of men aged over 80 years.

Major players in the drugs for benign prostatic hypertrophy market are Allergan PLC., Astellas Pharma Inc., Boehringer Ingelheim, Eli Lilly and Company, GlaxoSmithKline PLC., Teva Pharmaceutical Industries Limited, Sanofi, Nymox Pharmaceutical Corporation, and AEternaZentaris Inc.

Increasing adoption of minimally invasive surgeries due to advancements in technology is restraining the growth of the Benign Prostatic Hyperplasia drugs market. Minimally invasive surgeries cause less pain and are generally conducted on an outpatient basis. This eliminates the need to consume Benign Prostatic Hyperplasia drugs, acting as a restraint on the market. Some of the minimally invasive surgeries used to treat Benign Prostatic Hyperplasia include laparoscopic prostatectomy, transurethral microwave thermotherapy (TUMT), and transurethral needle ablation (TUNA).

Combination drugs are increasingly being used in the treatment of Benign Prostatic Hypertrophy as they are more effective and help prevent disease progression. A combination drug includes two or more active pharmaceutical ingredients (APIs) combined in a single dosage form. These drugs reduce the development of drug resistance, have fewer side effects, and low treatment failure rate. For instance, Duodart, a combination of dutasteride and tamsulosin hydrochloride is increasingly being prescribed for the treatment of Benign Prostatic Hypertrophy.

Benign prostatic hypertrophy drug manufacturers globally are regulated by various regulatory bodies. For instance, in the European Union, the EU legislation authorizes medicines based on quality, safety, and efficacy. Companies are mandated to submit compliance documentation for suitable quality before applying for authorization. Manufacturers are required to demonstrate the safety and efficacy of drugs using clinical trial data, which will be assessed by competent authorities before authorizing for sale.

North America was the largest region in the drugs for benign prostatic hypertrophy market in 2022. Middle East is expected to be the fastest-growing region in the global drugs for benign prostatic hypertrophy market share. The regions covered in the global drugs for benign prostatic hypertrophy market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The countries covered in the drugs for benign prostatic hypertrophy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The drugs for benign postratic hypertrophy market consists of sales of alfuzosin (Uroxatral), doxazosin (Cardura), tamsulosin (Flomax) and silodosin (Rapaflo). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The drugs for benign prostatic hypertrophy market research report is one of a series of new reports from The Business Research Company that provides drugs for benign prostatic hypertrophy market statistics, including drugs for benign prostatic hypertrophy industry global market size, regional shares, competitors with drugs for benign prostatic hypertrophy market share, detailed drugs for benign prostatic hypertrophy market segments, market trends and opportunities, and any further data you may need to thrive in the drugs for benign prostatic hypertrophy industry. This drugs for benign prostatic hypertrophy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

    Table Of Contents

    1. Executive Summary

    2. Drugs For Benign Prostatic hypertrophy Market Characteristics

    3. Drugs For Benign Prostatic hypertrophy Market Trends And Strategies

    4. Drugs For Benign Prostatic hypertrophy Market – Macro Economic Scenario

    4.1 COVID-19 Impact On Drugs For Benign Prostatic hypertrophy Market

    4.2 Ukraine-Russia War Impact On Drugs For Benign Prostatic hypertrophy Market

    4.3 Impact Of High Inflation On Drugs For Benign Prostatic hypertrophy Market

    5. Drugs For Benign Prostatic hypertrophy Market Size And Growth

    5.1. Global Drugs For Benign Prostatic hypertrophy Historic Market, 2017-2022, $ Billion

    5.1.1. Drivers Of The Market

    5.1.2. Restraints On The Market

    5.2. Global Drugs For Benign Prostatic hypertrophy Forecast Market, 2022-2027F, 2032F, $ Billion

    5.2.1. Drivers Of The Market

    5.2.2. Restraints On the Market

    6. Drugs For Benign Prostatic hypertrophy Market Segmentation

    6.1. Global Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Alpha Blocker

    5-alpha Reductase Inhibitor

    Phosphodiesterase-5 Inhibitor

    Other Types

    6.2. Global Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Hospital Pharmacies

    Retail Pharmacies

    Other End Users

    6.3. Global Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Hospital Pharmacies

    Retail Pharmacies

    Online Pharmacies

    7. Drugs For Benign Prostatic hypertrophy Market Regional And Country Analysis

    7.1. Global Drugs For Benign Prostatic hypertrophy Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    7.2. Global Drugs For Benign Prostatic hypertrophy Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    8. Asia-Pacific Drugs For Benign Prostatic hypertrophy Market

    8.1. Asia-Pacific Drugs For Benign Prostatic hypertrophy Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    8.3. Asia-Pacific Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    9. China Drugs For Benign Prostatic hypertrophy Market

    9.1. China Drugs For Benign Prostatic hypertrophy Market Overview

    9.2. China Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

    9.3. China Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

    10. India Drugs For Benign Prostatic hypertrophy Market

    10.1. India Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    10.2. India Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    11. Japan Drugs For Benign Prostatic hypertrophy Market

    11.1. Japan Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    11.2. Japan Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    12. Australia Drugs For Benign Prostatic hypertrophy Market

    12.1. Australia Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    12.2. Australia Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    13. Indonesia Drugs For Benign Prostatic hypertrophy Market

    13.1. Indonesia Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    13.2. Indonesia Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    14. South Korea Drugs For Benign Prostatic hypertrophy Market

    14.1. South Korea Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    14.2. South Korea Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    15. Western Europe Drugs For Benign Prostatic hypertrophy Market

    15.1. Western Europe Drugs For Benign Prostatic hypertrophy Market Overview

    15.2. Western Europe Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    15.3. Western Europe Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    16. UK Drugs For Benign Prostatic hypertrophy Market

    16.1. UK Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    16.2. UK Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    17. Germany Drugs For Benign Prostatic hypertrophy Market

    17.1. Germany Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    17.2. Germany Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    18. France Drugs For Benign Prostatic hypertrophy Market

    18.4. France Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    18.5. France Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    19. Eastern Europe Drugs For Benign Prostatic hypertrophy Market

    19.1. Eastern Europe Drugs For Benign Prostatic hypertrophy Market Overview

    19.2. Eastern Europe Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    19.3. Eastern Europe Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    20. Russia Drugs For Benign Prostatic hypertrophy Market

    20.1. Russia Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    20.2. Russia Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    21. North America Drugs For Benign Prostatic hypertrophy Market

    21.1. North America Drugs For Benign Prostatic hypertrophy Market Overview

    21.2. North America Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    21.3. North America Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    22. USA Drugs For Benign Prostatic hypertrophy Market

    22.1. USA Drugs For Benign Prostatic hypertrophy Market Overview

    22.2. USA Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    22.3. USA Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    23. South America Drugs For Benign Prostatic hypertrophy Market

    23.1. South America Drugs For Benign Prostatic hypertrophy Market Overview

    23.2. South America Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    23.3. South America Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    24. Brazil Drugs For Benign Prostatic hypertrophy Market

    24.1. Brazil Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    24.2. Brazil Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    25. Middle East Drugs For Benign Prostatic hypertrophy Market

    25.1. Middle East Drugs For Benign Prostatic hypertrophy Market Overview

    25.2. Middle East Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    25.3. Middle East Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    26. Africa Drugs For Benign Prostatic hypertrophy Market

    26.1. Africa Drugs For Benign Prostatic hypertrophy Market Overview

    26.2. Africa Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    26.3. Africa Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    27. Drugs For Benign Prostatic hypertrophy Market Competitive Landscape And Company Profiles

    27.1. Drugs For Benign Prostatic hypertrophy Market Competitive Landscape

    27.2. Drugs For Benign Prostatic hypertrophy Market Company Profiles

    27.2.1. Allergan PLC

    27.2.1.1. Overview

    27.2.1.2. Products and Services

    27.2.1.3. Strategy

    27.2.1.4. Financial Performance

    27.2.2. Astellas Pharma Inc.

    27.2.2.1. Overview

    27.2.2.2. Products and Services

    27.2.2.3. Strategy

    27.2.2.4. Financial Performance

    27.2.3. Boehringer Ingelheim

    27.2.3.1. Overview

    27.2.3.2. Products and Services

    27.2.3.3. Strategy

    27.2.3.4. Financial Performance

    27.2.4. Eli Lilly and Company

    27.2.4.1. Overview

    27.2.4.2. Products and Services

    27.2.4.3. Strategy

    27.2.4.4. Financial Performance

    27.2.5. GlaxoSmithKline PLC

    27.2.5.1. Overview

    27.2.5.2. Products and Services

    27.2.5.3. Strategy

    27.2.5.4. Financial Performance

    28. Drugs For Benign Prostatic hypertrophy Pipeline Analysis

    29. Key Mergers And Acquisitions In The Drugs For Benign Prostatic hypertrophy Market

    30. Drugs For Benign Prostatic hypertrophy Market Future Outlook and Potential Analysis

    31. Appendix

    31.1. Abbreviations

    31.2. Currencies

    31.3. Historic And Forecast Inflation Rates

    31.4. Research Inquiries

    31.5. The Business Research Company

    31.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2017-2022, $ Billion
  • Table 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Table 3: Global Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 4: Global Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 5: Global Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 6: Global Drugs For Benign Prostatic hypertrophy Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 7: Global Drugs For Benign Prostatic hypertrophy Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 8: Asia-Pacific, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 9: Asia-Pacific, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 10: China, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 11: China, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 12: India, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 13: India, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 14: Japan, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 15: Japan, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 16: Australia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 17: Australia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 18: Indonesia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 19: Indonesia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 20: South Korea, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 21: South Korea, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 22: Western Europe, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 23: Western Europe, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 24: UK, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 25: UK, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 26: Germany, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 27: Germany, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 28: France, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 29: France, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 30: Eastern Europe, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 31: Eastern Europe, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 32: Russia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 33: Russia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 34: North America, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 35: North America, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 36: USA, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 37: USA, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 38: South America, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 39: South America, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 40: Brazil, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 41: Brazil, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 42: Middle East, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 43: Middle East, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 44: Africa, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 45: Africa, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 46: Allergan PLC Financial Performance
  • Table 47: Astellas Pharma Inc. Financial Performance
  • Table 48: Boehringer Ingelheim Financial Performance
  • Table 49: Eli Lilly and Company Financial Performance
  • Table 50: GlaxoSmithKline PLC Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2017-2022, $ Billion
  • Figure 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Figure 3: Global Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 4: Global Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 5: Global Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 6: Global Drugs For Benign Prostatic hypertrophy Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 7: Global Drugs For Benign Prostatic hypertrophy Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 8: Asia-Pacific, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 9: Asia-Pacific, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 10: China, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 11: China, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 12: India, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 13: India, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 14: Japan, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 15: Japan, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 16: Australia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 17: Australia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 18: Indonesia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 19: Indonesia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 20: South Korea, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 21: South Korea, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 22: Western Europe, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 23: Western Europe, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 24: UK, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 25: UK, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 26: Germany, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 27: Germany, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 28: France, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 29: France, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 30: Eastern Europe, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 31: Eastern Europe, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 32: Russia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 33: Russia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 34: North America, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 35: North America, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 36: USA, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 37: USA, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 38: South America, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 39: South America, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 40: Brazil, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 41: Brazil, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 42: Middle East, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 43: Middle East, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 44: Africa, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 45: Africa, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 46: Allergan PLC Financial Performance
  • Figure 47: Astellas Pharma Inc. Financial Performance
  • Figure 48: Boehringer Ingelheim Financial Performance
  • Figure 49: Eli Lilly and Company Financial Performance
  • Figure 50: GlaxoSmithKline PLC Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report